Bioequivalence study of two esomeprazole enteric coated formulations in healthy Chinese volunteers

Abstract

A bioequivalence study of two esomeprazole (CAS 119141-88-7) enteric-coated formulations was carried out in 20 healthy Chinese volunteers according to a single dose, two-sequence, crossover randomized design. The two formulations were administered in two treatment days, separated by a washout period of 7 days. Blood samples were collected at specified time intervals over 10 h post-dosing. Plasma samples were separated and assayed for esomeprazole using a selective and sensitive HPLC method with UV detection. The pharmacokinetic parameters AUC_0–12h, AUC_max, C_max, t _max, t _1/2 and MRT were determined from the plasma concentration-time profile of both formulations. ANOVA and two one-sided t-test procedures showed no significant difference in log-transformed C_max, AUC_0–12h and AUC_0–∞ while the 90% confidence interval (CI) of the ratio of the geometric means of their values were also used to assess bioequivalence between the two formulations. The results of this study indicated that the two esomeprazole formulations can be considered to be bioequivalent.

Key words

Bioequivalence - Esomeprazole - Pharmacokinetics - Proton pump inhibitor

• References

• 1 DeVault KR, Castell DO. For the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100: 190-200
• 2 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005; 59: 709-15
• 3 Welage IS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc. 2000; 40: 52-62
• 4 Welage IS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy. 2003; 23: 74-80
• 5 Cotton H, Elebring T, Larsson M, Li L, Sorensen H, Unge SV. Asymmetric synthesis of esomeprazole. Tetrahedron Asymm. 2002; 11: 3819-25
• 6 Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009; 5: 1113-24
• 7 Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in management of acid-related disorders. Drugs. 2002; 62: 1503-38
• 8 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64: 935-51
• 9 Andersson T, Bredberg E, Sunzel M. Pharmacokinetics and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole and R-omeprazole. Gastroenterology. 2000; 118: A1210
• 10 Abelö A, Andersson TB, Antonsson M, Naudot AK, Skån-berg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000; 28: 966-72
• 11 Li J, Zhao J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther. 2006; 28: 419-27
• 12 Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000; 38: 243-70
• 13 Martín de Argila C. Safety of potent gastric acid inhibition. Drugs. 2005; 65 (Suppl 1) 97-104
• 14 Ullah MA, Shams Ud-Dowla, Maruf AA, Azad MA, Shohag MH, Sultana R et al. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy bangladeshi male volunteers: an open-label, single-dose, randomized-sequence, two-way crossover study. Clin Ther. 2010; 32: 1419-26